Ratings Synektik Spólka Akcyjna

Equities

SNT

PLSNKTK00019

Market Closed - Warsaw S.E. Other stock markets 11:55:56 2024-05-31 am EDT			5-day change	1st Jan Change
140 ^PLN	-2.10%		-1.13%	+62.79%

May. 06	Synektik with Climamedic signs System Supply Agreement Worth PLN 17.7 Million Net with Hospital in Warsaw	CI
Feb. 26	Synektik Announces Dividend for the Financial Year Ended on September 30, 2023, Payable on March 8, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company returns high margins, thereby supporting business profitability.
The company is in a robust financial situation considering its net cash and margin position.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
SYNEKTIK SPÓLKA AKCYJNA	+62.79%	303M	-
THERMO FISHER SCIENTIFIC	+7.01%	217B	B
DANAHER CORPORATION	+11.01%	190B	B-
INTUITIVE SURGICAL, INC.	+19.20%	143B	B-
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B	A-
SIEMENS HEALTHINEERS AG	+1.48%	64.59B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B	B+
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B	A
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.6B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes